Mechanistic description
The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.
Mechanism / pathway
- C1QA
- neurodegeneration
Evidence for (1)
Concrete next test: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses
Evidence against (1)
Promotion before replication would weaken quality control.
Evidence matrix
Supporting
- Concrete next test: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses SDA-2026-04-28-microglial-priming-causal-nd
Contradicting
- Promotion before replication would weaken quality control. SDA-2026-04-28-microglial-priming-causal-nd
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). microglial priming across neurodegenerative diseases should remain under review…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-9a9ad9ae54
@misc{scidex_hypothesis_h9a9ad9a,
title = {microglial priming across neurodegenerative diseases should remain under review…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-9a9ad9ae54},
note = {SciDEX artifact hypothesis:h-9a9ad9ae54}
}